Study guide
18.1 Biological Deposits & Sequence Listings
USPTO Registration Examination Patent Bar
Track your progress as you read
Finished sections get a check mark.
1 Chapter 1: Overview, Registration & MPEP Structure
1.1 Patent Bar Exam Format & Administration 1.2 Practitioner Qualifications & Eligibility 1.3 MPEP Structure & Effective Search Strategies
2 Chapter 2: Subject Matter Eligibility & Utility (35 U.S.C. § 101)
2.1 Patent-Eligible Subject Matter & Statutory Categories 2.2 Judicial Exceptions & the Alice/Mayo Framework 2.3 Utility Requirements & USPTO Utility Guidelines
3 Chapter 3: Novelty & Prior Art Under the AIA (35 U.S.C. § 102)
3.1 First-Inventor-to-File (FITF) & Effective Filing Dates 3.2 The One-Year Inventor Grace Period & Exceptions 3.3 Prior Art Types & Public Availability Standards
4 Chapter 4: Nonobviousness Analysis (35 U.S.C. § 103)
4.1 The Graham Factors & KSR Obviousness Framework 4.2 Combining Prior Art References & Motivation to Combine 4.3 Overcoming § 103 Rejections & Rule 132 Affidavits
5 Chapter 5: Specification & Disclosure Requirements (35 U.S.C. § 112(a))
5.1 Written Description Requirement 5.2 Enablement Requirement & Wands Factors 5.3 Best Mode Requirement & Current Post-AIA Status
6 Chapter 6: Claim Requirements & Definiteness (35 U.S.C. § 112(b)-(f))
6.1 Definiteness & Claim Precision 6.2 Independent & Dependent Claim Construction 6.3 Special Claim Formats: Means-Plus-Function & Markush Claims
7 Chapter 7: Application Types & Filing Procedures (MPEP Chapter 600)
7.1 Provisional Patent Applications 7.2 Nonprovisional Application Parts & Formalities 7.3 Inventor Oaths, Declarations & Assignments
8 Chapter 8: Duty of Disclosure & Information Disclosure Statements
8.1 Duty of Candor & Good Faith 8.2 Information Disclosure Statements (IDS) Requirements 8.3 Correcting Non-Disclosure & Duty Compliance
9 Chapter 9: Patent Prosecution & Office Action Responses (MPEP Chapter 700)
9.1 Initial Examination & Non-Final Office Actions 9.2 Statutory Deadlines & Extension of Time 9.3 Final Office Actions & Post-Final Practice
10 Chapter 10: Continuing Applications & Copendency
10.1 Continuation Applications 10.2 Divisional Applications 10.3 Continuation-in-Part (CIP) Applications & Priority Allocation
11 Chapter 11: Appeals & Interferences/Derivation (MPEP Chapter 1200 & 2300)
11.1 Ex Parte Appeals to the PTAB 11.2 PTAB Appeal Decisions & Judicial Review 11.3 Derivation Proceedings Under the AIA
12 Chapter 12: Post-Grant Proceedings & Corrections (MPEP Chapters 1400 & 2200)
12.1 Reissue Applications & Certificates of Correction 12.2 Ex Parte Reexamination & Supplemental Examination 12.3 Inter Partes Review (IPR) & Post-Grant Review (PGR)
13 Chapter 13: Patent Term, Maintenance Fees & Ownership
13.1 Patent Term Calculation & Patent Term Adjustment (PTA) 13.2 Maintenance Fees & Expiration 13.3 Inventorship, Ownership & Assignment Recordation 13.4 Patent Term Extension Under 35 U.S.C. § 156
14 Chapter 14: International Patent Practice & PCT (MPEP Chapter 1800)
14.1 The Patent Cooperation Treaty (PCT) Overview 14.2 PCT International Phase & Chapter I / Chapter II 14.3 National Phase Entry Under 35 U.S.C. § 371
15 Chapter 15: Special Patent Categories & Professional Conduct
15.1 Design Patents & Plant Patents 15.2 USPTO Rules of Professional Conduct 15.3 Patent Bar Exam Strategy & Open-Book Navigation Tips
16 Chapter 16: Security, Access, Representation & Filing Mechanics
16.1 Secrecy, Application Access & Foreign Filing Licenses 16.2 Representation, Power of Attorney & Correspondence 16.3 Filing Receipt, Certificates of Transmission & Signatures
17 Chapter 17: Restriction, Publication, Allowance & Office Authority
17.1 Restriction, Election, Rejoinder & Double Patenting 17.2 Publication, Preissuance Submissions & Protests 17.3 Allowance, Issue Fee & Withdrawal from Issue 17.4 Examiner Interviews, Petitions & Office Authority
18 Chapter 18: Biotechnology Disclosure & Patent Prosecution Highway
18.1 Biological Deposits & Sequence Listings 18.2 Global/IP5 Patent Prosecution Highway
19 Chapter 19: AIA Trial Practice Under the Consolidated Guide
19.1 AIA Trial Petitions, Preliminary Response & Institution 19.2 AIA Trial Discovery, Motions, Hearing & Final Decision
18.1 Biological Deposits & Sequence Listings
Key Takeaways Explain This Topic AI
A biological deposit can support enablement and written description when the public cannot otherwise make or obtain the biological material from the application disclosure.
A qualifying deposit generally must remain viable and publicly available under the rule when the patent grants; Budapest Treaty international depositary authorities can satisfy recognized deposit requirements.
Applications filed on or after July 1, 2022 that disclose nucleotide or amino-acid sequences within the rule use a WIPO ST.26-compliant XML sequence listing.
A sequence listing cannot cure missing original disclosure or add new matter; the specification and listing must be consistent and supported as of the filing date.
Last updated: August 2026
- 18.1 Biological Deposits & Sequence Listings
- Why biotechnology has special disclosure mechanics
The ordinary requirements of 35 U.S.C. § 112(a) apply to biotechnology: the application must show possession of the claimed invention and teach a skilled person to make and use it without undue experimentation. Some biological material cannot be adequately reproduced from words, structures, and laboratory steps alone. A cell line, hybridoma, plasmid, microorganism, or other self-replicating material may be unavailable to the public and difficult to describe so another laboratory can recreate it.
Rules 1.801–1.809 allow a deposit of biological material to supplement the written disclosure. A deposit is not automatically required in every biotechnology case. It becomes important when access to the particular material is necessary to practice the invention and the material is not otherwise known and readily available. If the disclosure enables the invention without access to a sample, the absence of a deposit is not itself a defect.
Timing and sufficiency of a deposit
A deposit made before filing offers the clearest evidence that the material existed and was available to support the disclosure. The rules can permit a deposit during pendency, but it must be completed early enough to satisfy the examiner and all regulatory statements before issue. A late deposit cannot add an invention that was absent from the application as filed. The original specification must identify and describe the material with sufficient correlation to show that the deposited material is what the application disclosed.
The applicant supplies the accession number, deposit date, name and address of the depository, and a description linking the deposit to the specification. The depository must be able to maintain and furnish viable samples for the required period. An International Depositary Authority recognized under the Budapest Treaty is commonly used because one qualifying deposit can be recognized by member offices.
Public access, viability, and replacement
The rules require irrevocable authorization for the depository to furnish samples under the specified conditions once the patent issues, and access can arise earlier in circumstances defined by the rules. The deposit must remain available for at least the regulatory storage period. The applicant cannot use private contract restrictions to defeat the access required for the patent disclosure.
If deposited material becomes nonviable, contaminated, or unavailable, the patent owner or applicant may need a replacement deposit . A replacement must represent the same biological material and be accompanied by required statements. Replacing the sample is not permission to substitute a materially different organism or construct; that would raise identity and new-matter concerns.
Sequence listings: ST.26 versus ST.25
Separate rules govern nucleotide and amino-acid sequence disclosures. For applications filed on or after July 1, 2022 , Rules 1.831–1.835 require a sequence listing in WIPO Standard ST.26 XML when the application contains sequences within the defined thresholds and exclusions. The listing is a structured XML file, not the older text-format listing used under ST.25. Earlier applications generally remain governed by the transition rules applicable to their filing date.
An ST.26 listing organizes sequences, feature annotations, source information, residues, and permitted qualifiers in a machine-readable form. The applicant files it as a separate part of the disclosure through the accepted electronic channel and refers to it in the specification as required. The rules distinguish a compliant XML sequence listing from tables or narrative sequence discussion that may also appear in the application.
The relevant filing date is the application’s actual filing date, not the date of a later response. A continuation filed after July 1, 2022 generally must satisfy ST.26 even if its parent used ST.25, while retaining substantive support from the parent remains a separate § 120 question.
Missing parts, corrections, and new matter
Formal defects—invalid XML, missing required qualifiers, or an inconsistent sequence identifier—can be corrected during prosecution. But 35 U.S.C. § 132 prohibits new matter. A corrected listing may clarify or reformat information already present; it cannot introduce a sequence never disclosed, change residues to create a new embodiment, or supply a functional relationship missing from the original specification while retaining the original filing benefit.
The examiner can require a compliant listing and may suspend or delay examination until it is supplied. A listing helps searching and examination, but it does not by itself prove utility, enablement, written description, or patent eligibility.
Comparison checklist
Mechanism Problem addressed Cannot do
Biological deposit Makes necessary biological material available Replace missing original identification of the invention
- Budapest Treaty deposit Provides recognized international depository framework Guarantee patentability
- ST.26 XML listing Standardizes disclosed nucleotide/amino-acid sequences Add unsupported sequences
- Replacement deposit Restores access to the same deposited material Substitute a materially different invention
For an exam scenario, ask first whether physical access is needed, then whether the deposit existed and is properly identified. For sequence problems, anchor the governing format to the application filing date and conduct a separate new-matter analysis.